Cannabis Oil Ends Seizures in 19 Drug-Resistant Epilepsy Patients
“My child went from hundreds of seizures a week to none.”
That’s not a slogan – it’s a reality echoed across 19 families in a groundbreaking new case series. Published in Frontiers in Neurology (2025), this study documents what few in neurology dare to promise: seizure freedom for patients with drug-resistant epilepsy, achieved through medical cannabis oil therapy. Every single one of them.
For some families, the search for relief from epilepsy never ends until cannabis oil enters the story.
A newly published case series has sent shockwaves through the clinical community: 19 patients with drug-resistant epilepsy all achieved seizure freedom through medical cannabis oil therapy. The study, published in Frontiers in Neurology (May 2025), doesn’t just document relief. It challenges long-held assumptions in neurology and policy alike.
A Turning Point for Treatment-Resistant Epilepsy
One of the patients was a young boy diagnosed with Doose syndrome, a severe childhood epilepsy that had already resisted over a dozen anti-seizure medications, dietary therapies, and device-based interventions. Before starting cannabis oil therapy, he was experiencing frequent drop seizures and tonic-clonic events every day, many of which resulted in injury or emergency intervention. His family had exhausted nearly every option, until a carefully titrated cannabis oil, rich in both CBD and low-dose THC, was prescribed through a licensed Canadian medical provider.
Within just a few weeks, his seizures began to decline. By month six, he had reached complete seizure freedom. His speech and balance began to improve. The constant anxiety and hospital visits became a memory. According to the study, he has remained seizure-free since.
For decades, patients with refractory epilepsy have faced an uphill battle. Even with access to modern anti-seizure medications (ASMs), nearly 30 percent of cases remain unresponsive. Side effects, developmental delay, cognitive harm, and in some cases, life-threatening consequences follow.
But in this peer-reviewed Canadian case series, conducted by neurologists and researchers affiliated with North Toronto Neurology, Krembil Brain Institute, and University of Toronto, a different story emerged. One rooted in cannabis-based medicine.
All 19 patients had previously failed multiple conventional treatments and were still experiencing seizures when they began cannabis oil therapy. Within months, every single one of them reached seizure freedom. A clinical milestone rarely seen in such severe cases.
“This series presents a potential paradigm shift in the treatment of drug-resistant epilepsy,” the authors write, urging further study and systemic reevaluation.
What Was Used?
The oils used in this study were not isolates like pure CBD, nor were they recreational products. While the researchers did not explicitly use the term “full-spectrum,” the formulations were clearly multi-cannabinoid in nature; either balanced THC:CBD oils or high-CBD, low-THC extracts. This strongly suggests they were broad- or full-spectrum oils, containing a range of cannabinoids working in synergy. This is a crucial point. THC, often misunderstood or demonized, was part of several treatment protocols. For many patients, it was not a problem to overcome but a key part of what worked. When THC is combined with CBD and other cannabinoids, the entourage effect can offer more comprehensive seizure control than isolates alone. Sadly, these combinations often take the back-seat in policy and perception, despite what the science, and this case series, clearly shows.
The cannabis oil formulations were not recreational off-the-shelf products. Each was prescribed by licensed Canadian medical professionals and sourced through legal medical channels, often as balanced THC:CBD oils or high-CBD, low-THC extracts tailored to each case. Doses varied widely depending on patient age, severity, and formulation, but all were titrated cautiously with ongoing medical oversight.
In many instances, families initiated cannabis therapy only after exhausting dozens of pharmacological and surgical options, including ketogenic diets, VNS implants, or resective brain surgeries.
This wasn’t anecdotal hope. It was documented transformation.
Who Were the Patients?
The patients in this series were diverse:
- Ages ranged from early childhood to adulthood
- Diagnoses included Dravet syndrome, Lennox-Gastaut, Doose syndrome, and other catastrophic epilepsy variants
- All had previously tried 4 to 20 or more conventional treatments
- Many had hundreds of seizures per month
Despite their differences, all shared the same outcome: seizure freedom.
The average time to full seizure control after starting cannabis oil? Just under 7 months.
Side Effects and Safety
Unlike many prescription ASMs, cannabis oils in this study were well tolerated, with only mild to moderate side effects reported in a few cases; typically sedation or appetite changes, both of which are often resolved over time or with dosage adjustments.
No patients experienced worsening of seizures, behavioral decline, or serious adverse reactions.
For a group that had already endured some of the harshest effects of pharmaceutical interventions, cannabis oil proved not only effective but remarkably safe.
Why This Matters
In Canada and beyond, epilepsy remains one of the leading reasons why families turn to medical cannabis, often after every other system has failed them. Until recently, evidence supporting its use was dismissed or limited to isolated success stories, small trials, or single-compound treatments like CBD isolate.
This new case series changes that. It validates what parents, patients, and pioneers have been saying for years: whole-plant cannabis oil, guided by proper dosing and professional oversight, has the power to do what pharmaceuticals alone cannot.
These 19 cases are not miracles. They are evidence. They prove that with access, support, and education, seizure freedom is possible for patients once deemed incurable.
And yet, access to this treatment still depends on privilege, geography, and outdated drug policy; not medical need. That is unacceptable.
Cannabis is not an alternative. It is a legitimate, life-changing therapy. And it’s time the system caught up with the science.
The Authors Speak Out
The study’s lead clinicians, including Dr. Evan Cole Lewis, urged fellow professionals to rethink their reluctance around cannabis. Rather than viewing cannabinoids as an “alternative,” they propose a new framework: rational, individualized cannabis therapy, as essential as any mainstream treatment.
They also emphasize the need for national and international epilepsy guidelines to begin including cannabis oil as a serious option, not a last resort.
“The findings highlight a need for future observational and controlled studies,” they note, “and for medical professionals to consider cannabinoid therapy earlier in the treatment journey.”
Wares of Wisdom
The proof is here. The outcomes are real. Now it’s time to stop treating cannabis as a last resort and start recognizing it for what it truly is; a first line of hope for those left behind by the system.
What’s remarkable is not just the seizure freedom. It’s the freedom from hopelessness. This study doesn’t just tell a scientific story. It reminds us that families, patients, and caregivers have been fighting for this evidence all along.
Medical cannabis oil, when respected and properly applied, can transform lives once considered untreatable. For epilepsy patients living in the shadow of seizures, this case series is a beam of light. It’s also a call to action.
Patients deserve access. Doctors deserve training. Regulators need to catch up.
And the science? It’s already moved ahead. The only thing missing now is the will to follow.
Revolutionary Research on the ECS, cannabinoids and cannabis-based medicine for healthcare from a trusted nonprofit.
